诚信认证:
工商注册信息已核实!
SB1317
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
阿拉丁 | 生产商 | 上海 | 现货 |
货号 | CAS号 | 操作 |
---|---|---|
S127924-50mg | 937270-47-8 | 询价 |
S127924-10mg | 937270-47-8 | 询价 |
S127924-100mg | 937270-47-8 | 询价 |
S127924-5mg | 937270-47-8 | 询价 |
- 分子式 C23H24N4O
- 分子量372.46
属性
溶解性 | DMSO |
存贮条件 | 储存温度-20°C |
描述
生化机理 |
TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias. |
别名 | ; |
SB1317信息由上海阿拉丁生化科技股份有限公司为您提供,如您想了解更多关于SB1317报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途